Despite the indisputable progress that has been made in the field of diagnostics and treatment of bronchogenic carcinomas during the recent decades, the efficacy of the conventional chemotherapy is still not satisfactory. Assessment of the basic molecular prognostic/predictive factors can enable the use of personalised treatment.
Clinical application of molecular predictors (biomarkers) is the pre-requisite for successful targeted biological treatment.